UBS Raises Pfizer Stock Target, Maintains Neutral Rating on Seagen Optimism

Friday, 12 July 2024, 12:38

UBS has increased the stock target for Pfizer, while also maintaining a Neutral rating for Seagen due to its optimistic outlook. The move reflects UBS's confidence in the growth potential of Pfizer and the positive sentiment towards Seagen's prospects in the market. Investors should take note of these developments as they indicate potential opportunities in both companies, albeit with a cautious stance on Seagen's performance.

Investing.com — UBS Raises Pfizer Stock Target, Maintains Neutral Rating on Seagen Optimism

UBS Raises Pfizer Stock Target

UBS has revised the stock target for Pfizer, indicating a positive forecast for the company.

Maintains Neutral Rating on Seagen

UBS is optimistic about Seagen but has decided to uphold a Neutral rating for the company.

Confidence in Pfizer's Growth: UBS's increased target suggests a strong outlook for Pfizer.
Caution on Seagen: Despite optimism, the Neutral rating reflects a careful approach towards Seagen's performance.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

UBS Raises Pfizer Stock Target

Maintains Neutral Rating on Seagen

Related posts